Brian Hujdich - high out-of-pocket costs
YouTube ID: X_mwgr91gwk (Source: PHRMA)
Source: PHRMA - June 12, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
Virginia Ladd - high out-of-pocket costs
YouTube ID: umQVJbd_2ek (Source: PHRMA)
Source: PHRMA - June 12, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
Carl Schmid - high out-of-pocket costs
YouTube ID: -MBFSCyBrqo (Source: PHRMA)
Source: PHRMA - June 12, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
John Rice
Executive DirectorJohn M. Rice joined CEF in March 2003 and serves as the Foundation's Executive Director. In this role he is responsible for all Foundation activities, developing programs and initiatives that benefit Foundation contributors and enhance science education across the country.
John has two decades of experience working in the not-for-profit arena, focusing on member services, fundraising, program development and administration. Prior to joining the CEF staff, John's professional experience included working with a number of prominent national and international non-profit organizations. From 1998-2002 John serv...
Source: PHRMA - June 11, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
How are patients with chronic conditions who have exchange coverage affected by high out-of-pocket costs for medicines?
Margaret Barton-Burke on Exchanges
Submitted by Julie on Wed, 06/11/2014 - 13:50
The dramatic cost shifting to vulnerable populations that is taking place within the Health Insurance Exchanges is troubling. The Oncology Nursing Society (ONS) believes that access to cancer care is the right of all people. While the Affordable Care Act (ACA) expanded access to insurance coverage, unaffordable co-insurance payments continue to threaten access to cancer care.
Share
Email
Print
var switchTo5x = false;var __st_loadLate = true;s...
Source: PHRMA - June 11, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
Margaret Barton-Burke on Exchanges
The dramatic cost shifting to vulnerable populations that is taking place within the Health Insurance Exchanges is troubling. The Oncology Nursing Society (ONS) believes that access to cancer care is the right of all people. While the Affordable Care Act (ACA) expanded access to insurance coverage, unaffordable co-insurance payments continue to threaten access to cancer care.
The vast majority of plans in the Health Insurance Exchanges place an unreasonable out-of-pocket cost burden on patients by requiring significant co-insurance for the vital medications used to treat serious health conditions according to new research ...
Source: PHRMA - June 11, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
Margaret Barton-Burke
PresidentMargaret Barton-Burke, PhD, RN, FAAN, is the president of the Oncology Nursing Society (ONS). She is the Mary Ann Lee Endowed Professor of Oncology Nursing at the College of Nursing, University of Missouri-St. Louis, and a research scientist at Siteman Cancer Center in St. Louis. Dr. Barton-Burke is a Fellow of the American Academy of Nursing (FAAN). She is a founding member of the Massachusetts Pain Initiative, the Massachusetts Cancer Pain Initiative, and several other cancer nursing initiatives. She has received numerous fellowships and most recently was named to the American Association of Colleges of Nursing ...
Source: PHRMA - June 11, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
Angela Ostrom on Exchanges
People living with chronic conditions like epilepsy often rely on medications to maintain their quality of life, and approximately 2/3 of the nearly 3 million Americans with epilepsy have seizure control largely due to pharmaceutical treatments. The Affordable Care Act meant hope to those who were priced out of the market for health insurance. This hope can be diminished by hitting consumers with high costs at the pharmacy counter. High out-of-pocket costs may force individuals to choose between medications and other essential family costs. Faced with challenges to living expenses, food budgets, child care, and/o...
Source: PHRMA - June 11, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
Rafael Amado - Research Ecosystem
The crosstalk between all parties in the process of discovery, development and commercialization of medicines has undergone significant evolution in the recent past. Not so long ago, it was incredibly rare to see competing pharmaceutical companies working together to develop combinations of medicines, even when there was compelling rationale. Collaborations between industry and academia have been common but there have often been misalignments about objectives and incentives. Relationships between the government and pharmaceutical companies have been mostly confined to regulatory interactions in the context of drug appr...
Source: PHRMA - June 5, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
Rafael Amado
Senior Vice President, Oncology R&DRafael Amado is Senior Vice President, Oncology R&D at GlaxoSmithKline. He is accountable for integrating oncology R&D efforts from drug target identification through late-stage development and registration globally.
Rafael joined GSK in 2008 as Vice President, Medicine Development Leader for Votrient. In that capacity he was responsible for developing and executing the asset’s development strategy globally. He served in positions of increasing responsibility as Vice President, Oncology Solid Tumors and Senior Vice President, Oncology Development, to his current role of he...
Source: PHRMA - June 5, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
We all want to better prevent, treat and cure the many forms of cancer. How close is the collaborative research ecosystem to achieving these goals, and what do we have to do to get there?
Josh Schafer - Research Ecosystem
Submitted by Sabrina on Thu, 06/05/2014 - 11:14
Watch John Schafer's Video Response
Share
Email
Print
var switchTo5x = false;var __st_loadLate = true;stLight.options({"publisher":"dr-e0d16a36-b72f-d979-d8a1-314a351971a6"});
$('#shareSocial').click(function(e) { e.preventDefault(); openSocial(); });
function openSocial() {
$('#shareSocial').toggleClass('active');
$('#social').slideToggle();
}
Sign-up for Updates
Subscribe to R...
Source: PHRMA - June 5, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
Josh Schafer - Research Ecosystem
Watch John Schafer's Video Response
Collaboration amongst various entities across the research and development continuum are becoming more varied within the field of oncology. It is common for pharmaceutical companies to collaborate on clinical trials that test the effects of various drug combinations, or to partner to share commercial sales and marketing efforts. We are now also seeing these same companies partner with government agencies like the Food and Drug Administration (FDA) and National Institutes of Health (NIH). One such example is The Biomarkers Consortium, a research partnership managed by the Foundation for...
Source: PHRMA - June 5, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
Josh Schafer, MSc. MBA
Vice President, Oncology Global Marketing StrategyJoshua Schafer is Vice President, Oncology Global Marketing Strategy at Astellas Pharmaceuticals, which a global top 20 pharmaceutical company. In his current role Mr. Schafer is responsible for global strategy and commercial leadership for Astellas Pharmaceuticals’ oncology portfolio with revenues of approximately $1.5B. Most recently he led the global launch of Xtandi for prostate cancer. He is a member of the Oncology Leadership team responsible for long term strategic planning, portfolio asset prioritization, development planning, and investment decisions includ...
Source: PHRMA - June 5, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
Allyson Funk
Director of CommunicationsAlly is a Director of Communications at PhRMA focusing on Medicare, Medicaid, the Affordable Care Act, and other public programs. Her previous experience includes leading health communications for a large membership organization, supporting public affairs clients, and working for the governor of Louisiana. Ally enjoys travel, trying new restaurants and spending time with Buddy, her 9-year-old rescue Pomeranian. In the fall, she and her husband are almost always wearing Saints gear. Follow Ally on Twitter @AllyFunk.
@AllyFunkCatalyst ContributorsCompany: PhRMA (Source: PHRMA)
Source: PHRMA - June 3, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
Ken Thorpe
ChairmanKenneth Thorpe, Ph.D., is Chairman of the Partnership to Fight Chronic Disease (PFCD) and a Robert W. Woodruff Professor and Chair of the Department of Health Policy & Management in the Rollins School of Public Health at Emory University, Atlanta, Georgia. He also co-directs the Emory Center on Health Outcomes and Quality.
Guest Catalyst ContributorCompany: PFCD (Source: PHRMA)
Source: PHRMA - May 30, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
